Biopharmaceuticals company, Aclaris Therapeutics, Inc. (Nasdaq: ACRS) has failed to meet primary and secondary endpoints in a Phase 2b study of zunsemetinib (ATI-450), an investigational…
November 13, 2023
Tonix Pharmaceuticals Begins Enrollment for Bone Density Treatment in Autism Spectrum Disorder
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) has enrolled the first participant in an investigator-initiated Phase 2 study of TNX-1900 (intranasal potentiated oxytocin) for improving bone…
November 10, 2023
Lipella Pharmaceuticals Granted FDA Orphan Designation for Oral Graft-versus-Host Disease Drug
Lipella Pharmaceuticals (Nasdaq: LIPO) has received Orphan Drug Designation for its LP-310 drug candidate for oral Graft-versus-Host Disease (GvHD). LP-310 is the company’s clinical stage…
November 09, 2023
BioStem Technologies Awarded Q Code for VENDAJE AC®
Leading regenerative medicine company, BioStem Technologies (OTC:BSEM) has secured a CMS Q code for its VENDAJE AC® structural tissue allograft product. The Healthcare Common Procedure…
Company’s global network now spans 61 countries In today’s corporate update, Quoin Pharmaceuticals (Nasdaq: QNRX) CEO, Dr. Michael Myers, shared the company’s “significant progress across…
Lucid Diagnostics Inc. (Nasdaq: LUCD) a majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM) has launched the next generation of its EsoGuard® Esophageal DNA test for…
November 09, 2023
Ultrasound Express Selects CareCloud’s talkEHR Platform to Streamline Patient Experience
Healthcare technology company, CareCloud (Nasdaq: CCLD), has been selected by Ultrasound Express to help enhance its patient experience and streamline administrative processes. CareCloud’s talkEHR platform…
November 08, 2023
Microbot Medical Trademarks “One & Done®”
Microbot Medical (Nasdaq: MBOT) has been granted a registered trademark from the US Patent and Trademark Office for a feature of the company’s LIBERTY Robotic…
November 03, 2023
Cybin’s Psilocybin Drug Candidate Delivers Remarkable Interim Results, Prompt Relief from Depression
Biopharmaceutical company, Cybin Inc. (NYSE American: CYBN), has announced interim results for its Phase 2 clinical trial evaluating CYB003, its proprietary deuterated psilocybin analog. CYB003…
GeoVax Labs (Nasdaq: GOVX) has commenced its planned site expansion for a Phase 2 clinical trial investigating its next-generation COVID vaccine, GEO-CM04S1, as a primary…
November 02, 2023
Vaxart To Fight Norovirus in Children with Vaccine Candidate
Clinical-stage biotechnology company, Vaxart (Nasdaq: VXRT) has dosed the first subject in a Phase 1 clinical trial evaluating its oral pill bivalent norovirus vaccine candidate…
Pharmaceutical company, SciSparc Ltd’s (Nasdaq: SPRC) patent application for Combination of Opioids and N-Acylethanolamines for pain treatment granted by IP Australia. The company’s share price…